AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca has a “positive catalyst path ahead” in the near term given its oncology project pipelines, according to broker Jefferies, but earnings forecasts were lowered. A ‘hold' rating was for the FTSE 100-listed pharma company as analysts saw “limited upside from the current share price”.

AstraZeneca attractive in near term but patent cliffs loom, says broker

AstraZeneca is breaking out on the strength of its relative strength highs and as profits continue to grow. The post AstraZeneca Stock Hits New Relative Strength Highs, Reaches Buy Zone appeared first on Investor's Business Daily.

AstraZeneca Stock Hits New Relative Strength Highs, Reaches Buy Zone

WILMINGTON, Del.--( BUSINESS WIRE )--AstraZeneca is proud to announce $4 million in financial contributions to 52 nonprofit organizations through its second-annual Accelerate Change Together (ACT) on Health Equity: Community Solutions Challenge and National Strategic Collaborations. Building on the learnings and impact from its inaugural year, the 2022 contributions will support community-based, regional and national nonprofit programs working to advance health equity and enhance STEM (Science, Technology, Education and Mathematics) among historically excluded and disenfranchised populations in the US.

AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity

Shore Capital has reiterated its ‘buy' stance on pharma giant AstraZeneca following data on its late-stage breast cancer drugs presented at a San Antonio conference, AstraZeneca's projects have “the potential to reshape treatment outcomes” and “redefine the standard of care within breast cancer,” said the broker. Shore reiterated a price target of £127 by the end of 2023, up from almost £114 currently.

AstraZeneca a ‘buy' for project pipeline potential – broker

TOKYO & MUNICH & BASKING RIDGE, N.J.--( BUSINESS WIRE )--Updated results from the TROPION-PanTumor01 phase 1 trial showed datopotamab deruxtecan (Dato-DXd) continued to demonstrate encouraging responses in patients with heavily pretreated metastatic triple negative breast cancer (TNBC) and disease progression following standard treatment. Results were presented today as a poster presentation (Abstract #P6-10-03) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22).

Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials

TOKYO & MUNICH & BASKING RIDGE, N.J.--( BUSINESS WIRE )--Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22).

Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer

TOKYO & MUNICH, Germany & BASKING RIDGE, N.J.--( BUSINESS WIRE )--Updated results from the DESTINY-Breast03 phase 3 trial (Abstract #GS2-02) showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. These results and primary results from the DESTINY-Breast02 phase 3 trial (Abstract #GS2-01) will be presented today at the 2022 San Antonio Breast Cancer Symposium (#SABCS22), with the updated results from DESTINY-Breast03 simultaneously published in The Lancet.

ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03

PetMed Express

Investing in safe healthcare stocks may be an underrated strategy to deploy.

2 Stocks That Could Surprise Investors in 2023

The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.

AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal

WILMINGTON, Del.--( BUSINESS WIRE )--AstraZeneca will present 47 abstracts showcasing new data from across its hematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, December 10 to 13, 2022.

AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022

AstraZeneca PLC (LSE:AZN) said it has sold its manufacturing site in West Chester, Ohio to National Resilience, Inc., which plans to expand the site and support future growth of its medicines manufacturing capabilities.  "As part of our long-term strategy to ensure our global supply network remains fit for the future, we are continuously optimising our manufacturing footprint to meet the evolving needs of our pipeline and portfolio,” commented Andrew Wirths, senior vice president of AstraZeneca's Americas Supply Region.

AstraZeneca sells Ohio manufacturing plant to National Resilience

SAN DIEGO--( BUSINESS WIRE )--National Resilience, Inc. (Resilience) and AstraZeneca PLC announced today that the companies will establish a long-term biomanufacturing relationship in support of AstraZeneca's portfolio. Under the agreement, AstraZeneca will have strategic access to Resilience's end-to-end capabilities. Resilience will purchase AstraZeneca's manufacturing facility located in West Chester, Ohio and will manufacture select AstraZeneca medicines at the facility as part of a multi-year supply agreement. The companies anticipate completing the transaction in early 2023, subject to receipt of regulatory approvals and the satisfaction of other customary closing conditions. Upon closing, Resilience will acquire the West Chester site's operations and physical assets, retain the site's leadership and employees, and continue to invest in the workforce and facility.

Resilience to Establish a Biomanufacturing Partnership with AstraZeneca and Purchase AstraZeneca's Manufacturing Site in West Chester, Ohio

AstraZeneca PLC (LSE:AZN) will spend up to US$320mln to strengthen its cancer business with an acquisition specialising in an innovative cell therapy approach for hard-to-treat cancers. Amsterdam-based Neogene Therapeutics Inc focuses on next-generation T-cell receptor therapies (TCR-Ts) to treat patients with advanced solid tumours.

AstraZeneca adds focus on personalised cancer cell therapy with US$320mln acquisition

SANTA MONICA, Calif. & AMSTERDAM--( BUSINESS WIRE )--Neogene Therapeutics, Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), today announced it has entered into a definitive agreement to be acquired by AstraZeneca.

AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy

C4X Discovery Holdings PLC (AIM:C4XD) (C4XD) has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to US$402mln, for developing and commercialising its NRF2 Activator programme.   AstraZeneca will develop and commercialise an oral therapy for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD).

C4X Discovery signs exclusive global licence with AstraZeneca

C4XD signs exclusive global licence worth up to $402 million1 with AstraZeneca for the development and commercialisation of NRF2 Activator programme C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company MANCHESTER, ENGLAND / ACCESSWIRE / November 28, 2022 / C4X Discovery Holdings plc (AIM:C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million1, for its NRF2 Activator programme. AstraZeneca will develop and commercialise an oral therapy for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD).

C4XD Agreement with AstraZeneca

C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties

C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme

WILMINGTON, Del.--( BUSINESS WIRE )--AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, 2022.

AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022

Bristol-Myers

Both have outperformed the stock market this year.

2 Stocks to Buy Whether or Not a Recession Is Coming

The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.

AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use

AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.

AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod

TOKYO & MUNICH--( BUSINESS WIRE )--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer

The company trounced analyst profitability estimates for its latest quarter and raised its guidance.

Why AstraZeneca Stock Shot Higher Today

AstraZeneca PLC (NASDAQ:AZN ) Q3 2022 Earnings Conference Call November 10, 2022 6:45 AM ET Company Participants Andy Barnett - Head of Investor Relations Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO David Fredrickson - Executive Vice-President of Oncology Business Unit Susan Galbraith - EVP of Oncology Research & Development Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit Menelas Pangalos - EVP of BioPharmaceuticals R&D Marc Dunoyer - CEO of Alexion Leon Wang - EVP of International & China President Iskra Reic - EVP, Vaccines and Immune Therapies Conference Call Participants Simon Baker - Redburn Sachin Jain - BofA Securities Andrew Baum - Citi Timothy Anderson - Wolfe Research Mark Purcell - Morgan Stanley Stephen Scala - Cowen and Company James Gordon - JPMorgan Richard Parkes - BNP Paribas Exane Eric Le Berrigaud - Stifel Michael Leuchten - UBS Jo Walton - Credit Suisse Emmanuel Papadakis - Deutsche Bank Seamus Fernandez - Guggenheim Peter Welford - Jefferies Adam Karlsson - ABG Sundal Collier Luisa Hector - Berenberg Operator Good morning to those joining from the U.K. and the U.S., good afternoon to those in Central Europe, and good evening to those listening in Asia. Welcome, ladies and gentlemen, to AstraZeneca's Year-to-date and Q3 Results 2022 Conference Call for Investors and Analysts.

AstraZeneca PLC (AZN) Q3 2022 Earnings Call Transcript

AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged.

News for AstraZeneca Stock (AZN)